"The only other contender in the hospitalized space is CytoDyn Inc.'s (CYDY:OTCQB) monoclonal antibody leronlimab. Their drug is a CCR5 inhibitor that stops the trafficking of macrophages to the site of infection thereby restoring homeostasis to the immune system. This restored functionality allows the immune system to more efficiently clear the virus and allow the body to heal.

The company had excellent Phase 3 data that showed an 82% reduction in 14 day mortality and no safety signals. Despite their statistically significant mortality benefit, the FDA wanted more data so the company initiated trials in Brazil for severe and critical patients.

Its plan is to get regulatory approval in Brazil and also use some of the data as part of a meta analysis for its severe COVID-19 trial that took place in the United States. "

https://www.streetwisereports.com/article/202...-lock.html